Business Wire

kENUP Foundation: Vaccine Skepticism in Germany Multiplies With Novel COVID Vaccines

11.2.2021 14:35:00 EET | Business Wire | Press release

Share

The first representative study of COVID-19 vaccine skeptics, conducted by kENUP Foundation, the Swiss Academies of Arts and Sciences and the EIB Institute, identified the socioeconomic and consumer behavior profile, as well as the dominant values and positions of COVID-19 vaccines skeptics and examined potential strategies to increase willingness to get a COVID-19 vaccine in that cohort.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005455/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Most over- and underrepresented characteristics of vaccines skeptics (Graphic: kENUP Foundation)

Overall, 19.6% of the German population make up the COVID-19 vaccine skeptic group, those unlikely or very unlikely to take the jab once offered to them. Almost 84.2% of that group were not opposed to vaccines before the corona crisis. This means that 13.7 million new skeptics are contributing to the high COVID-19 anti-vaccine sentiment.

COVID-19 vaccine skepticism is mainly driven by the fear of long-term damage (66.0%), the fast approval process (54.7%) and fear of adverse health effects (53.0%). It correlates with corona virus denial: 21.7% of vaccine skeptics and 36.8% of long-term anti-vaccinationists disagree that COVID-19 causes serious health problems. Denial of the virus infecting many people worldwide is 21.8% and 40%, respectively for new skeptics and long-term anti-vaccinationists.

While 69.3% of all vaccine skeptics could be convinced to take the COVID-19 vaccine through factual assurances, 69.4% of long-term anti-vaccinationists state that nothing would convince them. On the assurances needed for attitudinal change within the overall cohort, exclusion of long-term damage (52.0%), proven effectiveness (40.8%) and the evidence that genes are not changed (32.0%) top the list. Also, neither celebrity endorsement nor prospects of long-distance travel are convincing skeptics to be vaccinated. Vaccine skeptics seem to have more trust in vaccines originating from Germany, the United States, and the United Kingdom. Vaccines from Russia, China and especially India have a low chance of approval by skeptics.

A prevailing lack of life meaning and political participation defines the cohort of vaccine skeptics: 89.2% feel that they have no influence over politics. Of the long-term anti-vaccinationists, 35.2% express existential fears and financial worries, with life lacking any perspective for 35.6% of them. In terms of political affiliation, the anti-vaccination group is predominantly AfD-leaning (43.0%, far-right), with support of FDP (liberal) and Die Linke (left) also over-represented, while affinity to SPD (centre-left), CDU/CSU (centre-right) and Die Grünen (green) remains significantly underrepresented. Anti-vaccination sentiments are much higher in people of non-Christian religions.

The full report and more information can be found at https://www.kenup.eu/press and https://www.covidx.eu

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
kENUP: Tobias Mac-Lean, maclean@kenup.eu, https://www.kenup.eu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release

Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo

OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 09:00:00 EEST | Press release

OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual

Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 06:49:00 EEST | Press release

Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release

An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye